> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves BioVex BLA Supplement
- URL: https://www.fdaweb.com/fda-approves-biovex-bla-supplement/
- Published: 2023-02-16T12:00:00.000Z
- Updated: 2026-09-14T18:16:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153801

FDA has approved a BLA supplement submitted 8/12/22 by Amgen’s BioVex unit to update the labeling and Medication Guide for talimogene laherparepvec, a melanoma treatment. The update reflects herpetic infection, including disseminated herpetic infection, as an adverse drug reaction with talimogene laherparepvec administration, FDA [says](https://www.fda.gov/media/165431/download?utm%5Fmedium=email&utm%5Fsource=govdelivery).